Melanoma cells exploit hnRNP C to bind a repressive site in tapasin (TAPBP) 3′UTR, lowering HLA‑I antigen presentation. Genetic/biochemical disruption of this interaction restores tapasin and boosts HLA‑I surface levels—implicating hnRNP C as a biomarker and target for T‑cell–based immunotherapy.